Vizient, Inc. announces the finalists for its fourth annual Innovation Challenge, an event designed to illuminate some of the best new ideas in healthcare today. The five companies were chosen from a pool of almost 60 submissions spanning 17 states and four countries. Areas of focus include medical devices, genomics, wearables, artificial intelligence and healthcare IT. The Innovation Challenge will be held September 30 during the Clinical Connections Summit at the Hyatt Regency Dallas.
Part pitch competition, part panel discussion, the Innovation Challenge finalists will each deliver a seven-minute presentation to an expected audience of roughly 2,200 attendees at the Vizient 2016 Clinical Connections Summit. Using real-time polling technology, each audience member gets a vote, and the firm receiving the most votes will be named the Innovation Challenge Winner of 2016 immediately after the presentations.
“The Vizient Innovation Challenge is an interactive and entertaining format that gives our members a firsthand look at five of the most compelling product ideas designed to help improve the quality and delivery of health care in our country,” said Byron Jobe, president, chief administrative and financial officer. “Vizient is a champion of innovation, and we wish all five companies tremendous success during the competition and beyond.”
The five contestants in the Innovation Challenge are:
• SwipeSense - Combines point-of-care hand hygiene with real-time usage data to eliminate dependence on manual observations and increases compliance with infection-control procedures.
• Diagnostic Photonics - The Foresee Imaging System places a live view of tissue microstructure at the physician's fingertips, providing immediate insight into tissue microstructure. With that information in hand, physicians can make more informed decisions and provide better care.
• Silvercloud Health - An interactive platform designed with tools and tactics to empower patients to manage their mental and behavioral health. The platform also offers social and supportive elements to provide the human touch that we associate with face-to-face support. All developed with the most up to date technology.
• 3Derm – Virtual tele-dermatology diagnostics. The 3Derm imaging system captures and delivers the same three views a dermatologist uses in an exam room, making remote visits virtually indistinguishable from current practice.
• Tute Genomics - From faster, more accurate laboratory results to better clinical decision making, the Tute Genomics Platform delivers the technology infrastructure and industry compliance your organization needs to build scalable, accessible genomic medicine in-house. The tool stores and manages large repositories of genomic data, validates and launches new diagnostic tests, interprets genomic findings and shares clinical insights within a multidisciplinary team and across an enterprise.
Source: Vizient, Inc.
Tackling Health Care-Associated Infections: SHEA’s Bold 10-Year Research Plan to Save Lives
December 12th 2024Discover SHEA's visionary 10-year plan to reduce HAIs by advancing infection prevention strategies, understanding transmission, and improving diagnostic practices for better patient outcomes.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
The Importance of Hand Hygiene in Clostridioides difficile Reduction
November 18th 2024Clostridioides difficile infections burden US healthcare. Electronic Hand Hygiene Monitoring (EHHMS) systems remind for soap and water. This study evaluates EHHMS effectiveness by comparing C difficile cases in 10 hospitals with CMS data, linking EHHMS use to reduced cases.